Dhage S. et. al., A genomic ruler to assess oncogenic transition between breast tumor and stroma, 10.1371/journal.pone.0205602, PLoS ONE, Oct 16, 2018 ➔

Roszik J. et. al., Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy, 10.3389/fimmu.2018.02102, Front. Immunol, Sep 19, 2018 ➔

Foulds G.A. et. al., Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer, 10.3389/fimmu.2018.02028, Front Immunol., Sep 11, 2018 ➔

Su B. et. al., hsa-miR-24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c-Myc/epithelial-mesenchymal transition axis, 10.3892/or.2018.6690, Oncol Rep., Sep 07, 2018 ➔

Sugio T. et. al., Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS, 10.1182/bloodadvances.2018018754, Blood Adv., Sep 07, 2018 ➔

Rodrigues D.N. et. al., Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer, 10.1172/JCI121924, JCI, Sep 04, 2018 ➔

Yuan X. et. al., GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression, https://doi.org/10.1038/s41388-018-0483-x, Oncogene, Sep 04, 2018 ➔

Jiang P. et. al., Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response, https://doi.org/10.1038/s41591-018-0136-1, Nature Med., Aug 20, 2018 ➔

Dhawan D. et. al., Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer, 10.1371/journal.pgen.1007571, PLoS Genetics, Aug 08, 2018 ➔

Kim S-S. et. al., Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor, 10.1080/2162402X.2018.1484982, Oncoimmunology, Aug 01, 2018 ➔

Ghaffari A. et. al., STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer, https://doi.org/10.1038/s41416-018-0188-5, Br. J. Cancer, Jul 26, 2018 ➔

Cottagiri M. et. al., In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity, https://doi.org/10.1038/s41423-018-0087-y, Cellular & Molecular Immunology , Jul 20, 2018 ➔

Niyongere S. et. al., Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML, https://doi.org/10.1038/s41375-018-0203-0, Leukemia, Jul 19, 2018 ➔

Crawford G. et. al., Epithelial damage and tissue γδ T cells promote a unique tumor-protective IgE response, https://doi.org/10.1038/s41590-018-0161-8, Nature Immunology, Jul 16, 2018 ➔

Wolf G.T. et. al., IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers, 10.2147/OTT.S165411, Onco. Targets. Ther., Jun 28, 2018 ➔